Janice Kuhn
7PUBLICATIONS
7CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (7)
Sort by Publication Date:
|May 29, 2021
Real-world cost estimates of initiating emicizumab in US patients with haemophilia A.Benjamin J Samelson-Jones, Christine Guelcher, Jan Kuhn
|Apr 29, 2021
An in vitro pharmacodynamic spiking study of befovacimab, a tissue factor pathway inhibitor monoclonal antibody, in blood samples from patients with severe FVIII deficiency.Erika J Martin, Melinda E Nolte, Janice Kuhn
|Apr 21, 2020
Real-world use of emicizumab in patients with haemophilia A: Bleeding outcomes and surgical procedures.Isabella McCary, Christine Guelcher, Jan Kuhn
|Jul 24, 2019
Marstacimab, a tissue factor pathway inhibitor neutralizing antibody, improves coagulation parameters of ex vivo dosed haemophilic blood and plasmas.Sunita Patel-Hett, Erika J Martin, Bassem M Mohammed
|Feb 13, 2019
Use of global assays to monitor emicizumab prophylactic therapy in patients with haemophilia A with inhibitors.Donald F Brophy, Erika J Martin, Janice Kuhn
|Aug 17, 2018
Evaluating the thrombin generation profiles of four different rFVIII products in FVIII-deficient plasma using FIXa and FXIa activation.Donald F Brophy, Erika J Martin, Marisa Ninivaggi
Pageof 2
